辉瑞公司上调了全年业绩指引，新产品的强劲势头帮助其抵消了新冠疫苗和治疗药物销售下滑的影响。
Pfizer boosted its guidance for the year, as momentum in new products helped it offset declining sales for its Covid-19 vaccine and treatments.
这家总部位于纽约的公司周二表示，其近期推出和收购的产品——包括癌症治疗药物Padcev和Lorbrena——在最新季度的销售额增长了32%。其他产品如抗凝血药Eliquis和心脏病治疗药Vyndaqel销售额的增加，也提振了公司的总营收。
The New York company said Tuesday that sales for its recently launched and acquired products—which include cancer treatments Padcev and Lorbrena—gained 32% in the latest quarter. Higher sales for other products, like blood thinner Eliquis and heart-disease treatment Vyndaqel, also boosted the company’s top line.